High levels of life sciences mergers and acquisitions in the tail-end of 2013 may make for a busy start to 2014, according to a report from PricewaterhouseCoopers.
Report: Strong M&A momentum as medtech moves into 2014
Medtech M&A analysis: 41 device companies sold in 2013
Total deal volume in the medical device industry contracted by about 13% in 2013, according to new analysis from audit shop PricewaterhouseCoopers.
Corporate funding, price transparency and failure: The road ahead for healthcare
Healthcare industry analysts at PricewaterhouseCoopers’ Health Research Institute have a few lessons for companies navigating what promises to be a turbulent year ahead, offering advice ranging from failing frugally to adapting to heightened transparency expectations.
Here are 3 of the most relevant foresights for the medical device industry, selected from HRI’s top 10:
Medtech a ‘bright spot’ in Q3 lifesciences investment, analysts say
There has been much recent hand-wringing about the lack of availability of funding for medtech startup, but analysts at PricewaterhouseCoopers see it a little differently.
Medtech VC deals decline, but value increases during Q3
Third-quarter investment in medical device companies by venture capital shops was down, but the value of the deals rose, according to the PricewaterhouseCoopers/National Venture Capital Assn. MoneyTree report.
The report, which uses data compiled by Thompson Reuters, found that the 65 medtech deals inked by VCs during the 3 months ended Sept. 30 was down 8% compared with the 2nd quarter. But the value of those deals, pegged at $566 million, rose 12% compared with Q2, according to the report.
Medtech investment: Deal volume drops in Q2, but analysts remain optimistic
There was good news and bad news in the latest life sciences deals report from the analysts at PricewaterhouseCoopers. Investment in the medical device industry took a hard downward turn year-over-year, but market trends signal that the life sciences market may expect a comeback before the end of 2013.
House committee slams FDA over $1B user fee balance
MASSDEVICE ON CALL — A U.S. House of Representatives committee slammed the FDA over the $1 billion in unobligated user fees the watchdog agency is carrying on its books.
MassDevice.com +7 | The top 7 med-tech stories for the week of May 13, 2013
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Medical device M&A: Activity still strong despite Q1 declines in deal value, volume
The number of medical device merger & acquisition deals and their value fell during the 1st quarter, according to PricewaterhouseCoopers, but that doesn’t mean there wasn’t a lot of activity behind the scenes, Dimitri Drone, leader of PricewaterhouseCoopers’ Transaction Services Life Sciences sector, told MassDevice.com.
5 opportunities for investment in China’s healthcare system
As the Chinese healthcare market grows at an unprecedented clip, investors should concentrate on a handful of opportunities that take advantage of economic and regulatory trends in the alluring emerging market, a new report from PricewaterhouseCoopers says.
Report: Medtech investments take a downward turn in Q1
Medical device industry venture capital investment dropped 20% in dollars in Q1, with 10% fewer deals reported compared with Q4 2012, according to a new funding report.
